Retrospective cohort study of the efficacy of caprylic triglyceride in patients with mild-to-moderate alzheimer’s disease

References

• Alzheimer’s Association2012Alzheimer’s disease facts and figures Available from: http://www.alz.org/alzheimers_disease_facts_and_figures.aspAccessed April 25, 2011
   Google Scholar
• Alzheimer’s AssociationChanging the trajectory of Alzheimer’s disease: a national imperative2010 Available at: http://www.alz.org/documents_custom/trajectory.pdfAccessed April 25, 2011
   Google Scholar
• GauthierSScheltensPCan we do better in developing new drugs for Alzheimer’s disease?Alzheimers Dement20095648949119896588
   PubMed Web of Science ®Google Scholar
• IhlRAnti-dementia drugs for dementia syndromes – just unkept promises?MMW Fortschr Med200622426 German
   Google Scholar
• RainaPSantaguidaPIsmailaAEffectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guidelineAnn Intern Med2008148537939718316756
   PubMed Web of Science ®Google Scholar
• MosconiLBrysMGlodzik-SobanskaLDe SantiSRusinekHde LeonMJEarly detection of Alzheimer’s disease using neuroimagingExp Gerontol2007421–212913816839732
   PubMed Web of Science ®Google Scholar
• ReimanEMChenKAlexanderGEFunctional brain abnormalities in young adults at genetic risk for late-onset Alzheimer’s dementiaProc Natl Acad Sci U S A2004101128428914688411
   PubMed Web of Science ®Google Scholar
• RobinsonAMWilliamsonDHPhysiological roles of ketone bodies as substrates and signals in mammalian tissuesPhysiol Rev19806011431876986618
   PubMed Web of Science ®Google Scholar
• CunnaneSNugentSRoyMBrain fuel metabolism, aging, and Alzheimer’s diseaseNutrition201127132021035308
   PubMed Web of Science ®Google Scholar
• HendersonSTVogelJLBarrLJGarvinFJonesJJCostantiniLCStudy of the ketogenic agent AC-1202 in mild to moderate Alzheimer’s disease: a randomized, double-blind, placebo-controlled, multicenter trialNutr Metab (Lond)200963119664276
   PubMed Web of Science ®Google Scholar
• VenemanTMitrakouAMokanMCryerPGerichJEffect of hyperketonemia and hyperlacticacidemia on symptoms, cognitive dysfunction, and counterregulatory hormone responses during hypoglycemia in normal humansDiabetes19944311131113177926305
   PubMed Web of Science ®Google Scholar
• HasselbalchSGMadsenPLHagemanLPChanges in cerebral blood flow and carbohydrate metabolism during acute hyperketonemiaAm J Physiol19962705 Pt 1E746E7518967461
   PubMed Web of Science ®Google Scholar
• KashiwayaYTakeshimaTMoriNNakashimaKClarkeKVeechRLD-beta-hydroxybutyrate protects neurons in models of Alzheimer’s and Parkinson’s diseaseProc Natl Acad Sci U S A200097105440544410805800
   PubMed Web of Science ®Google Scholar
• Van der AuweraIWeraSVan LeuvenFHendersonSTA ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer’s diseaseNutr Metab (Lond)200522816229744
   PubMedGoogle Scholar
• StafstromCERhoJMThe ketogenic diet as a treatment paradigm for diverse neurological disordersFront Pharmacol201235922509165
   PubMed Web of Science ®Google Scholar
• RegerMAHendersonSTHaleCEffects of beta-hydroxybutyrate on cognition in memory-impaired adultsNeurobiol Aging200425331131415123336
   PubMed Web of Science ®Google Scholar
• BabayanVKMedium chain triglycerides and structured lipidsLipids19872264174203112486
   PubMed Web of Science ®Google Scholar
• López-PousaSBermejo-ParejaFFrankAHernándezFLeónTRejas-Gutiérrez J;ECOThe effect of donepezil in comparison with conventional treatment on cognitive functioning and the performance of the patient in a prospective cohort of patients with Alzheimer’s disease treated in routine clinical practice in SpainRev Neurol20105110577588 Spanish21069636
   PubMed Web of Science ®Google Scholar
• SantoroASivieroPMinicuciNEffects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer’s disease: a prospective, observational studyCNS Drugs201024216317620088621
   PubMed Web of Science ®Google Scholar
• RiepeMWKohlerJHornRDonepezil in Alzheimer’s disease: a clinical observational study evaluating individual treatment responseCurr Med Res Opin20072381829183517599785
   PubMed Web of Science ®Google Scholar
• LawtonMPBrodyEMAssessment of older people: self-maintaining and instrumental activities of daily livingGerontologist1969931791865349366
   PubMed Web of Science ®Google Scholar
• ReisbergBGlobal measures: utility in defining and measuring treatment response in dementiaInt Psychogeriatr200719342145617480241
   PubMed Web of Science ®Google Scholar
• AshfordJWKumarVBarringerMAssessing Alzheimer severity with a global clinical scaleInt Psychogeriatr19924155741391672
   PubMedGoogle Scholar
• Alzheimer’s Research ForumNeuropsychological tests2009 Available from: http://www.alzforum.org/dis/dia/tes/neuropsychological.aspAccessed April 25, 2011
   Google Scholar
• CummingsJLMcRaeTZhangRDonepezil-Sertraline Study GroupEffects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disordersAm J Geriatr Psychiatry200614760561216816014
   PubMed Web of Science ®Google Scholar
• FroelichLAndreasenNTsolakiMLong-term treatment of patients with Alzheimer’s disease in primary and secondary care: results from an international surveyCurr Med Res Opin200925123059306819852697
   PubMed Web of Science ®Google Scholar
• FeldmanHHPirttilaTDartiguesJFTreatment with galantamine and time to nursing home placement in Alzheimer’s disease patients with and without cerebrovascular diseaseInt J Geriatr Psychiatry200924547948818985627
   PubMed Web of Science ®Google Scholar
• MinthonLWallinAKErikssonSWattmoCAndreasenNLong-term rivastigmine treatment in a routine clinical settingActa Neurol Scand2009119318018518759798
   PubMed Web of Science ®Google Scholar
• CortesFNourhashémiFGuérinOPrognosis of Alzheimer’s disease today: a two-year prospective study in 686 patients from the REAL-FR StudyAlzheimers Dement200841222918631947
   PubMed Web of Science ®Google Scholar
• BehlPStefurakTLBlackSEProgress in clinical neurosciences: cognitive markers of progression in Alzheimer’s diseaseCan J Neurol Sci200532214015116018149
   PubMed Web of Science ®Google Scholar
• Gillette-GuyonnetSAndrieuSNourhashemiFLong-term progression of Alzheimer’s disease in patients under antidementia drugsAlzheimers Dement20117657959222055975
   PubMed Web of Science ®Google Scholar
• MendiondoMSAshfordJWKryscioRJSchmittFAModelling Mini Mental State Examination changes in Alzheimer’s diseaseStat Med20001911–121607161610844722
   PubMed Web of Science ®Google Scholar
• HanLColeMBellavanceFMcCuskerJPrimeauFTracking cognitive decline in Alzheimer’s disease using the Mini-Mental State Examination: a meta-analysisInt Psychogeriatr200012223124710937543
   PubMed Web of Science ®Google Scholar
• Ravona-SpringerRLuoXSchmeidlerJThe association of age with rate of cognitive decline in elderly individuals residing in supporting care facilitiesAlzheimer Dis Assoc Disord201125431231621572311
   PubMed Web of Science ®Google Scholar
• PavlikVNDoodyRSMassmanPJChanWInfluence of premorbid IQ and education on progression of Alzheimer’s diseaseDement Geriatr Cogn Disord200622436737716954693
   PubMed Web of Science ®Google Scholar
• FritschTMcClendonMJSmythKAEffects of educational attainment on the clinical expression of Alzheimer’s disease: results from a research registryAm J Alzheimers Dis Other Demen200116636937611765862
   PubMedGoogle Scholar
• DoodyRSMassmanPDunnJKA method for estimating progression rates in Alzheimer diseaseArch Neurol200158344945411255449
   PubMedGoogle Scholar
• TeriLMcCurrySMEdlandSDKukullWALarsonEBCognitive decline in Alzheimer’s disease: a longitudinal investigation of risk factors for accelerated declineJ Gerontol A Biol Sci Med Sci199550A1M49M557814789
   PubMed Web of Science ®Google Scholar
• SuhGHJuYSYeonBKShahAA longitudinal study of Alzheimer’s disease: rates of cognitive and functional declineInt J Geriatr Psychiatry200419981782415352138
   PubMed Web of Science ®Google Scholar
• MungasDReedBREllisWGJagustWJThe effects of age on rate of progression of Alzheimer disease and dementia with associated cerebrovascular diseaseArch Neurol20015881243124711493164
   PubMedGoogle Scholar
• ErnstRLHayJWThe US economic and social costs of Alzheimer’s disease revisitedAm J Public Health1994848126112648059882
   PubMed Web of Science ®Google Scholar
• EvansJDHeatonRKPaulsenJSPalmerBWPattersonTJesteDVThe relationship of neuropsychological abilities to specific domains of functional capacity in older schizophrenia patientsBiol Psychiatry200353542243012614995
   PubMed Web of Science ®Google Scholar
• BurdickDJRosenblattASamusQMPredictors of functional impairment in residents of assisted-living facilities: the Maryland Assisted Living studyJ Gerontol A Biol Sci Med Sci200560225826415814872
   PubMed Web of Science ®Google Scholar
• GreenCRMohsRCSchmeidlerJAryanMDavisKLFunctional decline in Alzheimer’s disease: a longitudinal studyJ Am Geriatr Soc19934166546618505464
   PubMed Web of Science ®Google Scholar
• FarlowMRAlvaGMengXOlinJTA 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer’s disease: a post hoc analysisCurr Med Res Opin201026226326919929593
   PubMed Web of Science ®Google Scholar
• BenoitMRobertPHStacciniPOne-year longitudinal evaluation of neuropsychiatric symptoms in Alzheimer’s disease. The REAL.FR StudyJ Nutr Health Aging200592959915791352
   PubMed Web of Science ®Google Scholar
• TrinhNHHoblynJMohantySYaffeKEfficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysisJAMA2003289221021612517232
   PubMed Web of Science ®Google Scholar
• MaaloufMRhoJMMattsonMPThe neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodiesBrain Res Rev200959229331518845187
   PubMedGoogle Scholar
• BaliettiMGiorgettiBFattorettiPKetogenic diets cause opposing changes in synaptic morphology in CA1 hippocampus and dentate gyrus of late-adult ratsRejuvenation Res200811363164018593281
   PubMed Web of Science ®Google Scholar